WilmerHale Advises Translate Bio on Collaboration with Sanofi Pasteur

WilmerHale Advises Translate Bio on Collaboration with Sanofi Pasteur

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On March 27, 2020, Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced a collaboration to develop a novel mRNA vaccine for COVID-19 with Sanofi Pasteur, the vaccines global business unit of Sanofi. The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development. This collaboration leverages an existing agreement from 2018 between Translate Bio and Sanofi Pasteur to develop mRNA vaccines for infectious diseases.

The WilmerHale team representing Translate Bio was led by Steve Singer, Ariel Soiffer and Cynthia Mazareas.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel